FDA Q-Submission Program 2025: What Medical Device Innovators Need to Know
The FDA’s Q-Submission Program (as updated in May 2025) represents one of the most powerful tools available to medical device developers seeking to de-risk regulatory pathways and accelerate time-to-market. For companies navigating complex device classifications, novel technologies, or uncertain regulatory requirements, the strategic use of Q-Submissions can mean the difference between smooth approval processes and costly delays.
At Biomedical Statistical Consulting® (BSC®), we’ve supported hundreds of successful FDA submissions over our 35+ years of regulatory biostatistics expertise. Our experience with Q-Submissions spans from early-stage Pre-Subs for breakthrough orthopedic and spine devices to complex Study Risk Determinations for AI-powered diagnostics.
What Is the Q-Submission (Q-Sub) Program?
The Q-Submission Program enables medical device companies to seek feedback and request meetings with the FDA before formally submitting marketing or investigational applications. These touchpoints can lead to more efficient development and review processes for new medical devices.
- Pre-Submission (Pre-Sub): Request written feedback on specific questions before an intended submission. ~70 days target response.
- Submission Issue Request (SIR): Get input on resolving issues flagged in a hold letter on an open submission. 21–70 days.
- Study Risk Determination: Ask FDA to determine if a proposed clinical study is significant risk, nonsignificant risk, or exempt. Typically within 90 days.
- Informational Meeting: Share information with FDA with no expectation of feedback. Typically within 90 days.
- PMA Day 100 Meeting: Review status of an original PMA ≤100 days after FDA files the application.
When NOT to Use the Q-Sub Program
You should not submit a Q-Sub if you only need administrative clarifications, your question is about device classification (use a 513(g) instead), your inquiry relates to an active review, the topic is a formal appeal, or the request involves Emergency Use Authorization.
Strategic Timing Considerations
Early Engagement: The most successful companies use Q-Submissions as part of a broader regulatory strategy from the earliest stages of device development. Consider submitting a Pre-Sub during the design control phase, particularly when your device incorporates novel technologies, AI/ML algorithms, or addresses unmet clinical needs.
Clinical Trial Planning: For devices requiring clinical data, submit Pre-Subs 6–12 months before planned study initiation.
Breakthrough Device Integration: Companies pursuing Breakthrough Device Designation should coordinate Q-Sub timing with their designation request.
Common Pitfalls and How to Avoid Them
Question Formulation Errors: Many companies submit overly broad questions. Structure questions around specific regulatory pathways, predicate device comparisons, or particular aspects of your development plan.
Documentation Gaps: Ensure your Q-Sub includes sufficient technical detail. Include comprehensive device descriptions, intended use statements, preliminary design information, and any relevant preclinical data.
Key Takeaways for a Successful Q-Sub
- Be Clear and Specific: Identify your device, intended use, and key questions
- Limit the Scope: FDA recommends focusing on no more than 3–4 substantial topics per submission
- Plan Ahead: Pre-Subs are best submitted well before clinical studies begin
- Follow Documentation Best Practices: Include a cover letter with detailed contact info and a clear request type
- Leverage Electronic Submissions: Use the CDRH Portal or FDA Electronic Submission Gateway
- Keep Records: All Q-Subs are confidential within the bounds of law
Updates in 2025
The May 2025 guidance aligns with FDA’s ongoing efforts under MDUFA V, clarifies the boundaries of Q-Sub versus other communication pathways, and provides enhanced examples of well-structured questions to maximize FDA engagement.
Conclusion
Getting FDA feedback early and often through the Q-Submission Program represents one of the smartest investments medical device companies can make in their regulatory strategy. Whether you’re developing breakthrough spinal implants, AI-powered diagnostics, or complex combination products, the Q-Submission pathway can provide the regulatory clarity and confidence needed to move forward decisively.
Ready to leverage the Q-Submission Program for your next regulatory milestone? Contact BSC® today to discuss how strategic Q-Submission planning can accelerate your path to market.
Congratulations to BSC®’s David Maislin, Alex Breno, and our friends at 3Spine on their recent publication!
The article lays out the protocol for the pivotal IDE trial behind 3Spine's MOTUS® lumbar Total Joint Replacement, the first device built to restore both disc and facet joint function without sacrificing motion.
WHAT CLIENTS SAY
“They listen the first time. I’ve never had to go back and respell out what I needed."
”They work to understand the problem and leverage the information that is already there.”
Former FDA Regulator
WHAT CLIENTS SAY
"Battle ground tested."
"There is nothing that David and team haven’t seen over the years – the good, bad, and ugly.”
Vice President, Clinical Operations
WHAT CLIENTS SAY
"Get stuff done when you have to do something no one else has done before."
"They aren’t afraid to tackle difficult scenarios in compressed timelines."
CEO, Medical Device Company
Regulatory-first biostatistics
Support built specifically for FDA-facing programs, from early feasibility through submission and post-market requirements.
Direct communication, faster turn around
Our biostatisticians write the SAP and run the analysis. One person owns both — no separate programmer, no project manager in between.
Versatile Solutions
Engage us for a focused analysis or a full submission, We size the work to the problem.
Proven FDA Experience
Hands-On Experience with FDA Pathways, statistical reviews, and regular interactions, reducing risk and rework.